Sample identification and attrition summary
| Remaining | ||
|---|---|---|
| Criteria | n | Per cent |
| Laboratory result indicating HbA1c ≥9% (index date) | 45 865 | 100 |
| Age <18 or >89 with no enrolment gap | 40 980 | 89 |
| Continuous enrolment ≥12 months preindex and ≥36 months postindex | 16 553 | 36 |
| Research eligible members (eg, non-ASO plan members) | 12 856 | 28 |
| Diagnosis of type 2 diabetes during the preindex period | 11 861 | 26 |
| Exclusion of members with a diagnosis of T1DM during the study period | 8774 | 19 |
| Primary and secondary diagnosis of type 2 diabetes (medical and Rx claims) | 8605 | 19 |
| No diagnosis of gestational diabetes or pregnancy during the study period | 8496 | 19 |
| No pharmacy claims over the 48-month study period | 8464 | 18 |
| Complete demographic data (ie, gender) | 8463 | 18 |
| Final sample size | 8463 | 18 |
ASO, administrative services only; HbA1c, glycosylated hemoglobin; T1DM, type 1 diabetes mellitus.